Calcium Channel Blockers Pharmacology

Quick Answer

Calcium channel blockers (CCBs) inhibit voltage-gated L-type calcium channels, reducing calcium influx into cardiac and vascular smooth muscle cells. Classification is based on chemical structure: dihydropyridines (nifedipine, amlodipine, nimodipine, nicardipine) with predominant vascular selectivity, and non-dihydropyridines comprising phenylalkylamines (verapamil) with cardiac selectivity and benzothiazepines (diltiazem) with intermediate effects. Verapamil and diltiazem produce significant negative inotropy, chronotropy, and dromotropy, making them useful for supraventricular arrhythmias but hazardous when combined with beta-blockers or in heart failure. Dihydropyridines cause peripheral vasodilation with reflex tachycardia but minimal direct cardiac effects. Nimodipine is uniquely selective for cerebral vasculature (cerebral vasospasm post-subarachnoid haemorrhage), while nicardipine is used intravenously for acute hypertension and stroke. Key anaesthetic interactions include enhanced hypotension with volatile agents (additive L-type channel blockade) and severe bradycardia/heart block with beta-blockers. CCB toxicity management includes calcium chloride, high-dose insulin-euglycaemia therapy, vasopressors, and lipid emulsion as rescue therapy. [1-8]

Calcium Channel Physiology

Voltage-Gated Calcium Channels

Voltage-gated calcium channels (VGCCs) are transmembrane proteins that permit calcium influx in response to membrane depolarisation. They are classified according to their activation threshold and tissue distribution: [9-11]

Channel Types:

L-Type Calcium Channels

L-type (long-lasting) calcium channels are the primary target of clinically used CCBs. They consist of multiple subunits: [9,12]

Subunit Structure:

The alpha-1C subunit is the functional core containing:

• Four homologous domains (I-IV), each with six transmembrane segments (S1-S6)
• S4 segment: Voltage sensor with positively charged arginine residues
• Pore region: Between S5 and S6, contains selectivity filter
• Drug binding sites: Distinct sites for dihydropyridines, phenylalkylamines, and benzothiazepines

L-Type Channels in Cardiac Muscle

In cardiomyocytes, L-type channels mediate excitation-contraction coupling through calcium-induced calcium release (CICR): [10,11]

Mechanism:

1. Action potential depolarisation opens L-type channels
2. Small calcium influx ("trigger calcium") enters cytoplasm
3. Trigger calcium binds ryanodine receptors (RyR2) on sarcoplasmic reticulum
4. Massive calcium release from SR stores
5. Calcium binds troponin C, enabling cross-bridge cycling and contraction
6. Relaxation via SERCA2a (SR Ca-ATPase) and NCX (Na/Ca exchanger)

Role in Cardiac Action Potential:

In SA and AV nodes, L-type channels contribute to the action potential upstroke (no fast sodium channels present), making these tissues sensitive to CCB effects.

L-Type Channels in Vascular Smooth Muscle

In vascular smooth muscle, L-type channel activation causes: [13]

• Calcium influx and increased cytoplasmic calcium
• Activation of myosin light chain kinase (MLCK)
• Phosphorylation of myosin light chains
• Cross-bridge formation and vasoconstriction

Vascular smooth muscle has a more depolarised resting membrane potential (-40 to -55 mV) compared to cardiac muscle (-80 to -90 mV), resulting in greater L-type channel activity. This explains why dihydropyridines preferentially affect vascular tissue.

T-Type Calcium Channels

T-type (transient) channels activate at more negative potentials and inactivate rapidly: [14]

Cardiac Functions:

• Contribute to pacemaker depolarisation in SA node
• Modulate AV nodal conduction
• Involved in cardiac hypertrophy pathophysiology

Clinical Relevance:

• Mibefradil (withdrawn) was selective for T-type channels
• Some CCBs (verapamil, mibefradil) have partial T-type blockade
• T-type blockade may contribute to anti-hypertensive effects

Classification of Calcium Channel Blockers

Chemical Classification

CCBs are classified by chemical structure, which determines tissue selectivity and clinical effects: [1-3]

Classification Table:

Binding Site Specificity

Each CCB class binds to distinct but allosterically coupled sites on the alpha-1C subunit: [15,16]

Dihydropyridines:

• Bind to the extracellular side of the pore region (Domain III-IV interface)
• Preferential binding to inactivated (depolarised) channels
• Voltage-dependent binding explains vascular selectivity (more depolarised VSM)
• State-dependent: Higher affinity for channels in depolarised membranes

Phenylalkylamines (Verapamil):

• Bind to intracellular pore region (Domain IV S6 segment)
• Access binding site only when channel is open ("use-dependent" blockade)
• Binding enhanced by high heart rate and depolarisation
• Greater effect on frequently firing cardiac tissue

Benzothiazepines (Diltiazem):

• Bind to a site overlapping but distinct from both DHPs and phenylalkylamines
• Intermediate properties between the two classes
• Some use-dependence but less than verapamil

Tissue Selectivity Comparison

Mechanism of Action

Molecular Mechanism

CCBs produce their effects by blocking the alpha-1C subunit of L-type calcium channels: [1,2,9]

Binding and Blockade:

1. CCB binds to specific site on alpha-1C subunit
2. Conformational change reduces channel open probability
3. Decreased calcium influx during depolarisation
4. Reduced intracellular calcium concentration
5. Tissue-specific downstream effects

State-Dependent Binding:

This explains:

• Use-dependence of verapamil: Greater effect on rapidly firing tissue (SVT)
• Vascular selectivity of DHPs: Preferential binding to depolarised vascular smooth muscle

Cardiovascular Effects

Effects on Cardiac Muscle:

Verapamil and Diltiazem:

• Reduce SA node automaticity (negative chronotropy)
• Slow AV nodal conduction (negative dromotropy, prolonged PR interval)
• Reduce myocardial contractility (negative inotropy)
• Useful for rate control in atrial fibrillation/flutter
• Contraindicated in heart failure with reduced ejection fraction

Dihydropyridines:

• Potent peripheral vasodilation (afterload reduction)
• Minimal direct cardiac effects at clinical doses
• Reflex sympathetic activation causes tachycardia
• No significant effect on cardiac conduction

Vascular Effects

All CCBs cause vasodilation, but with different selectivity: [3,4]

Vascular Bed Selectivity:

Nimodipine demonstrates preferential cerebral vascular selectivity due to higher lipophilicity allowing BBB penetration and greater affinity for cerebral vascular smooth muscle L-type channels.

Individual Drug Profiles

Verapamil

Classification: Phenylalkylamine, cardiac-selective CCB

Pharmacokinetics: [17,18]

Pharmacodynamics:

• Most potent negative inotrope among CCBs
• Marked AV nodal blockade (prolongs AH interval on electrophysiology study)
• Slows SA node automaticity
• Moderate peripheral vasodilation
• Constipation (smooth muscle effect) in 25% of patients

Clinical Applications:

• Supraventricular tachycardia (acute termination and prophylaxis)
• Atrial fibrillation/flutter rate control
• Angina pectoris (reduces myocardial oxygen demand)
• Hypertension (sustained-release formulations)
• Hypertrophic cardiomyopathy (improves diastolic relaxation)

Dosing:

Contraindications:

• Heart failure with reduced EF
• Second/third degree AV block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Concurrent beta-blocker therapy (relative)
• Wolff-Parkinson-White syndrome with atrial fibrillation
• Hypotension (SBP less than 90 mmHg)

Diltiazem

Classification: Benzothiazepine, intermediate selectivity

Pharmacokinetics: [19,20]

Pharmacodynamics:

• Moderate negative inotropy (less than verapamil)
• Moderate AV nodal blockade
• Peripheral vasodilation (coronary and systemic)
• Better tolerated than verapamil in borderline LV function
• Less constipation than verapamil

Clinical Applications:

• Atrial fibrillation/flutter rate control (first-line with beta-blockers)
• Chronic stable angina
• Hypertension
• Acute coronary syndromes (non-ST elevation)

Dosing:

Advantages over Verapamil:

• Less negative inotropy
• Less constipation
• IV infusion more commonly available

Nifedipine

Classification: Dihydropyridine, vascular-selective

Pharmacokinetics: [21]

Pharmacodynamics:

• Potent peripheral vasodilator
• Minimal direct cardiac effects
• Reflex tachycardia (sympathetic activation)
• Coronary vasodilation
• No effect on cardiac conduction

Clinical Considerations:

• Short-acting nifedipine capsules are NOT recommended for hypertension due to precipitous BP drops, reflex tachycardia, and associated myocardial ischaemia/stroke
• Extended-release formulations provide smooth BP control
• Useful in Raynaud's phenomenon

Dosing:

• Oral extended-release: 30-90 mg once daily
• Avoid sublingual/immediate-release for hypertensive emergencies

Amlodipine

Classification: Dihydropyridine, long-acting

Pharmacokinetics: [22]

Pharmacodynamics:

• Gradual onset of action (minimal reflex tachycardia)
• Sustained 24-hour BP control
• No significant negative inotropy
• Well-tolerated in heart failure (PRAISE trial)
• Peripheral oedema more common than other DHPs

Clinical Applications:

• Hypertension (first-line, especially in elderly and African populations)
• Chronic stable angina
• Vasospastic (Prinzmetal) angina
• Safe in heart failure (unlike verapamil/diltiazem)

Evidence Base:

• ALLHAT trial: Amlodipine equivalent to chlorthalidone for cardiovascular outcomes [23]
• ASCOT-BPLA: Amlodipine-based regimen superior to atenolol-based for cardiovascular events [24]

Dosing:

• Oral: 5-10 mg once daily
• Start 5 mg in elderly or hepatic impairment
• No renal dose adjustment required

Nimodipine

Classification: Dihydropyridine, cerebral vascular-selective

Pharmacokinetics: [25]

Cerebral Selectivity: Nimodipine's preferential cerebral vascular effect is attributed to:

• High lipophilicity enabling BBB penetration
• Greater affinity for cerebral vascular L-type channels
• Preferential binding to depolarised cerebral VSM (ischaemic tissue)

Clinical Application: Subarachnoid Haemorrhage

Nimodipine is the only CCB with proven benefit in aneurysmal SAH, reducing delayed cerebral ischaemia (DCI) and improving neurological outcomes: [26]

Evidence:

• Multiple RCTs demonstrate 40% reduction in poor outcomes
• Reduces DCI incidence (not angiographic vasospasm)
• Likely neuroprotective effects beyond vasodilation
• Cochrane review: Significant reduction in poor outcome (RR 0.67)

Dosing for SAH:

• Oral/NG: 60 mg every 4 hours for 21 days
• Start within 96 hours of SAH onset
• Continue even if surgical clipping/coiling performed
• IV formulation available (caution: severe hypotension)

Important Warnings:

• Do NOT administer IV nimodipine via oral route (severe hypotension, deaths reported)
• IV formulation requires central line and close BP monitoring
• Dose reduction in hepatic impairment

Nicardipine

Classification: Dihydropyridine, IV administration for acute hypertension

Pharmacokinetics: [27]

Clinical Applications:

• Acute hypertensive emergencies
• Perioperative hypertension
• Acute ischaemic stroke (BP management)
• Controlled hypotension

Advantages for Acute Hypertension:

• Titratable IV infusion
• Rapid onset with predictable dose-response
• No AV nodal effects
• Maintains cerebral, coronary, and renal perfusion
• Does not increase ICP

Dosing:

Stroke Considerations:

• Preferred agent for BP management in acute ischaemic stroke
• Does not increase ICP or cause cerebral vasodilation
• Smooth, predictable BP reduction

Pharmacokinetic Comparison

Absorption and Bioavailability

Metabolism

All CCBs undergo hepatic metabolism primarily via CYP3A4: [17-22]

Drug Interactions via CYP3A4:

Verapamil and Diltiazem as CYP3A4 Inhibitors:

• Both inhibit CYP3A4 and P-glycoprotein
• Increase levels of: statins (simvastatin, atorvastatin), cyclosporine, tacrolimus, digoxin
• Require dose adjustment of co-administered drugs

Half-Lives and Duration

Clinical Applications

Hypertension

CCBs are first-line antihypertensives, particularly effective in: [23,24]

• Elderly patients (reduced renin system)
• African/Caribbean populations
• Isolated systolic hypertension
• Patients intolerant of ACE inhibitors/ARBs

Recommendations:

• DHPs (amlodipine, nifedipine SR) preferred for uncomplicated hypertension
• Non-DHPs reserved for rate control indications
• Avoid combining non-DHP CCBs with beta-blockers

Angina Pectoris

Mechanism of Antianginal Effect:

• Reduced myocardial oxygen demand (rate, contractility, BP reduction)
• Coronary vasodilation (increased oxygen supply)
• Afterload reduction (DHPs)

Agent Selection:

Supraventricular Arrhythmias

Verapamil and Diltiazem Applications: [28]

Contraindication:

• Wolff-Parkinson-White syndrome with AF: AV nodal blockade may increase conduction down accessory pathway, precipitating VF

Cerebral Vasospasm

Nimodipine in SAH: [26]

Controlled Hypotension

Nicardipine Applications:

• Intracranial surgery (maintains cerebral perfusion)
• Vascular surgery (reduces wall tension)
• Perioperative hypertension
• Does not increase ICP

Anaesthetic Interactions

Volatile Anaesthetic Agents

CCBs and volatile agents both inhibit L-type calcium channels, producing additive or synergistic cardiovascular depression: [29,30]

Mechanisms:

• Both reduce calcium influx in cardiac and vascular smooth muscle
• Enhanced negative inotropy
• Enhanced vasodilation
• Potentiated conduction depression (non-DHPs)

Clinical Manifestations:

Volatile Agent Comparison:

• Sevoflurane and desflurane: Less myocardial depression than halothane
• Isoflurane: Moderate interaction
• Halothane (historical): Greatest interaction risk

Management Considerations:

• Do NOT discontinue chronic CCB therapy preoperatively (withdrawal risk)
• Anticipate enhanced hypotensive response
• Have calcium chloride available (1 g IV as antagonist)
• Reduce volatile agent concentration if significant hypotension
• Invasive monitoring for major surgery in patients on non-DHPs

Beta-Blocker Interaction

The combination of non-dihydropyridine CCBs with beta-blockers is potentially hazardous: [5,6]

Mechanisms:

• Additive negative chronotropy (SA node depression)
• Additive negative dromotropy (AV nodal blockade)
• Additive negative inotropy
• Both classes reduce calcium-dependent processes

Potential Consequences:

• Severe bradycardia (less than 40 bpm)
• Complete heart block
• Asystole
• Acute heart failure
• Cardiogenic shock

Risk Stratification:

Clinical Scenarios:

• DHP + beta-blocker: Often used together for angina (complementary effects)
• Never give IV verapamil to patient on beta-blocker (case reports of asystole)

Neuromuscular Blocking Agents

CCBs may potentiate neuromuscular blockade: [31]

Mechanisms:

• Reduced calcium entry at motor nerve terminal
• Decreased acetylcholine release
• Direct muscle membrane effects (minor)

Clinical Significance:

• Modest prolongation of NMB duration (10-30%)
• More significant with verapamil than DHPs
• Relevant with aminoglycoside antibiotics (additive)
• Monitor neuromuscular function; may need reduced NMB doses

Local Anaesthetic Toxicity

Verapamil is NOT recommended in local anaesthetic systemic toxicity (LAST): [32]

Rationale:

• LAST involves sodium channel blockade
• CCBs do not reverse sodium channel effects
• Verapamil may worsen cardiovascular collapse
• Lipid emulsion is the specific treatment for LAST

Other Drug Interactions

Adverse Effects and Toxicity

Common Adverse Effects

Dihydropyridines:

Non-Dihydropyridines:

Calcium Channel Blocker Toxicity

CCB overdose is a life-threatening emergency with high mortality: [7,8]

Clinical Presentation:

• Cardiovascular: Profound hypotension, bradycardia, heart block, asystole
• Metabolic: Hyperglycaemia (insulin resistance from beta-cell calcium blockade)
• Neurological: Altered consciousness (hypoperfusion)
• ECG: Prolonged PR (non-DHPs), wide QRS (severe), ST changes

Severity Markers:

• Shock (SBP less than 90 mmHg despite fluids)
• Severe bradycardia (less than 40 bpm)
• High-degree AV block
• Hyperglycaemia (poor prognostic sign)
• Lactate elevation

Toxicity Management

Standard Resuscitation Approach: [7,8]

High-Dose Insulin-Euglycaemia Therapy (HIE):

First-line treatment for severe CCB toxicity:

Vasopressors:

Lipid Emulsion Therapy:

Rescue therapy when standard treatment fails: [8]

Additional Measures:

• Glucagon: 5-10 mg IV bolus, then 2-10 mg/hr (limited evidence)
• Pacing: Transcutaneous or transvenous for refractory bradycardia
• ECMO: Consider for refractory cardiogenic shock
• Methylene blue: Case reports for refractory vasoplegia

Indigenous Health Considerations

Aboriginal and Torres Strait Islander peoples and Maori populations experience significantly higher rates of cardiovascular disease, with earlier onset and greater severity than non-Indigenous populations. Ischaemic heart disease, hypertension, and heart failure are major contributors to the life expectancy gap. Calcium channel blockers are frequently prescribed in these communities, requiring specific considerations for safe and effective use.

Cardiovascular Disease Burden: Indigenous Australians experience cardiovascular disease at 1.3 times the rate of non-Indigenous Australians, with mortality rates 1.5-2 times higher. Rheumatic heart disease, though rare in the general population, remains endemic in remote Indigenous communities (prevalence up to 2% in some regions). Heart failure secondary to rheumatic valvular disease may be present at younger ages, necessitating caution with negatively inotropic agents (verapamil, diltiazem).

Pharmacological Considerations: The higher prevalence of chronic kidney disease (3-4 times higher in Indigenous Australians) affects CCB selection. While most CCBs are hepatically metabolised, attention to overall cardiorenal status is essential. Amlodipine is preferred for hypertension management given its long half-life supporting once-daily dosing, lack of significant renal elimination, and safety in heart failure. Non-dihydropyridine CCBs require careful assessment of cardiac function before initiation.

Medication Access and Adherence: Many Indigenous communities are located in remote and very remote areas with limited healthcare access. Medication supply may be intermittent, favouring long-acting agents (amlodipine: 30-50 hour half-life) that maintain efficacy if doses are occasionally missed. The Pharmaceutical Benefits Scheme (PBS) Closing the Gap co-payment arrangements reduce medication costs for eligible patients. Aboriginal Health Workers and Aboriginal Health Practitioners provide crucial support for medication education, adherence monitoring, and early identification of adverse effects such as peripheral oedema.

Cultural Safety: Effective prescribing requires culturally safe practice, including clear explanations of medication purposes and potential side effects (swollen ankles, dizziness) in accessible language. Family and community involvement in health decisions aligns with Indigenous concepts of collective wellbeing. Visual aids and pictorial medication charts may support understanding. Telemedicine consultations enable specialist input for complex cardiovascular management in remote locations.

Maori Health (New Zealand): Maori populations experience similar cardiovascular disease disparities. Kaupapa Maori approaches to healthcare emphasise whanau (family) involvement and holistic wellbeing. Pharmacists and kaiwhina (community health workers) support medication understanding and adherence. The same pharmacological principles apply regarding agent selection and monitoring.

ANZCA Primary Exam Focus

High-Yield MCQ Topics

1. Classification: Dihydropyridines vs non-dihydropyridines, tissue selectivity
2. Mechanism: L-type channel blockade, state-dependent binding, use-dependence
3. Verapamil vs DHPs: Cardiac selectivity, negative inotropy, AV nodal effects
4. Nimodipine: Cerebral vasospasm, 60 mg every 4 hours for 21 days
5. Drug interactions: Beta-blockers (heart block), volatile agents (enhanced hypotension)
6. Toxicity management: Calcium, high-dose insulin, lipid emulsion
7. Pharmacokinetics: CYP3A4 metabolism, amlodipine long half-life

Viva Themes

• Comparison of CCB classes and tissue selectivity
• Management of CCB toxicity
• Perioperative CCB management and anaesthetic interactions
• Nimodipine in subarachnoid haemorrhage
• Drug interactions (beta-blockers, volatile agents)
• Selection of agent for specific clinical scenarios

Calculation Examples

Diltiazem Loading Dose: 70 kg patient, loading dose 0.25 mg/kg over 2 minutes = 0.25 x 70 = 17.5 mg (round to 15-20 mg)

Nicardipine Infusion: Starting rate 5 mg/hr, concentration 0.1 mg/mL (10 mg in 100 mL) = 5 mg/hr / 0.1 mg/mL = 50 mL/hr

Assessment Content

SAQ Practice Question (20 marks)

Question:

A 72-year-old woman with a history of hypertension and paroxysmal atrial fibrillation presents for elective total hip replacement. She takes amlodipine 10 mg daily and diltiazem SR 240 mg daily for rate control. Her resting heart rate is 64 bpm and blood pressure is 138/78 mmHg.

(a) Classify calcium channel blockers according to their chemical structure and describe the mechanism of action at the cellular level. (5 marks)

(b) Compare and contrast the pharmacological effects of amlodipine (dihydropyridine) and diltiazem (benzothiazepine) on the cardiovascular system. (5 marks)

(c) Discuss the potential interactions between calcium channel blockers and volatile anaesthetic agents. How would you manage this patient's anaesthesia? (5 marks)

(d) Intraoperatively, the patient becomes hypotensive (BP 72/48 mmHg) with a heart rate of 44 bpm. Outline your immediate management. (5 marks)

---

Model Answer:

(a) Classification and Mechanism of Action (5 marks)

Classification:

[1 mark for classification, 1 mark for examples]

Mechanism of Action:

• CCBs block voltage-gated L-type calcium channels [0.5]
• Bind to alpha-1C subunit of channel complex [0.5]
• Reduce calcium influx during membrane depolarisation [0.5]
• In cardiac muscle: Reduced excitation-contraction coupling, decreased contractility [0.5]
• In vascular smooth muscle: Reduced myosin light chain kinase activation, vasodilation [0.5]
• In nodal tissue: Slowed SA node automaticity, slowed AV conduction [0.5]

(b) Comparison of Amlodipine and Diltiazem (5 marks)

[0.5 marks for each correct comparison point, maximum 5 marks]

(c) Volatile Agent Interactions and Anaesthetic Management (5 marks)

Interaction Mechanisms:

• Both CCBs and volatile agents inhibit L-type calcium channels [0.5]
• Additive reduction in calcium influx [0.5]
• Enhanced hypotension (peripheral vasodilation) [0.5]
• Enhanced myocardial depression (especially with diltiazem) [0.5]
• Risk of bradycardia and conduction disturbances [0.5]

Management Approach:

• Continue both medications on morning of surgery (avoid withdrawal) [0.5]
• Anticipate enhanced hypotensive response to induction and maintenance [0.5]
• Ensure calcium chloride 10% (1 g) immediately available [0.5]
• Consider invasive arterial monitoring given dual CCB therapy [0.5]
• Careful titration of volatile agent concentration [0.5]
• Have vasopressors prepared (metaraminol, phenylephrine) [0.5]
• Avoid additional AV nodal blocking agents if possible [0.5]

[Maximum 5 marks for interaction and management]

(d) Management of Hypotension with Bradycardia (5 marks)

Immediate Assessment:

• Likely CCB-related cardiovascular depression potentiated by volatile agent [0.5]
• Reduce/cease volatile agent immediately [0.5]
• Call for help, inform surgeon [0.25]

Pharmacological Management:

• Atropine: 0.6-1.2 mg IV (may be ineffective in CCB excess) [0.5]
• Calcium chloride 10%: 1 g (10 mL) IV over 5 minutes [0.5]
  • Mechanism: Increases extracellular calcium to overcome competitive blockade [0.25]
  • May repeat if initial response inadequate [0.25]
• Vasopressor: Metaraminol 0.5-1 mg bolus or phenylephrine 100-200 mcg [0.5]

If Refractory:

• Adrenaline 10-50 mcg IV boluses [0.5]
• Consider glucagon 2-5 mg IV (increases cAMP independent of calcium) [0.25]
• Prepare for external pacing if complete heart block develops [0.25]
• Reduce surgical stimulation/bleeding if ongoing [0.25]

Ongoing Management:

• Invasive arterial line if not already in place [0.25]
• Reassess depth of anaesthesia [0.25]
• Consider TOE if available to assess cardiac function [0.25]

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Examiner: A 55-year-old man is admitted to ICU following a subarachnoid haemorrhage from a ruptured anterior communicating artery aneurysm. The aneurysm has been coiled. His neurosurgeon asks you to prescribe nimodipine. Please discuss this medication.

Candidate:

Purpose and Indication (2 marks):

"Nimodipine is a dihydropyridine calcium channel blocker with preferential selectivity for cerebral vasculature. It is indicated for the prevention of delayed cerebral ischaemia following aneurysmal subarachnoid haemorrhage.

Key evidence includes multiple randomised controlled trials demonstrating approximately 40% reduction in poor neurological outcomes. Notably, nimodipine reduces delayed cerebral ischaemia even though it doesn't consistently prevent angiographic vasospasm, suggesting additional neuroprotective mechanisms."

Examiner: What is the dosing regimen?

Candidate:

Dosing (2 marks):

"The standard regimen is 60 mg orally or via nasogastric tube every 4 hours for 21 days. Treatment should commence within 96 hours of the haemorrhage.

For patients who cannot tolerate oral administration or have significant hypotension, the dose may be reduced to 30 mg every 4 hours. An intravenous formulation exists but is rarely used due to the high risk of severe hypotension and requires central venous access with close monitoring."

Examiner: What are the important safety considerations?

Candidate:

Safety Considerations (3 marks):

"The most critical safety concern is that the intravenous formulation must NEVER be administered orally. There have been fatalities from inadvertent oral administration of IV nimodipine. The oral and IV preparations have vastly different concentrations.

Hypotension is the most common adverse effect and may necessitate dose reduction. Patients should have continuous blood pressure monitoring during the initial phase of treatment.

Drug interactions are significant as nimodipine is metabolised by CYP3A4. Strong CYP3A4 inhibitors such as azole antifungals, macrolide antibiotics, and grapefruit juice can significantly increase nimodipine levels and hypotensive effects.

Hepatic impairment requires dose reduction due to decreased clearance.

The short half-life of 1-2 hours means the 4-hourly dosing regimen must be strictly adhered to for therapeutic effect."

Examiner: The patient develops symptomatic vasospasm on day 7 with new neurological deficits. What is your approach?

Candidate:

Management of Symptomatic Vasospasm (3 marks):

"This represents delayed cerebral ischaemia, which is the complication nimodipine aims to prevent but does not eliminate.

Immediate Management:

• Continue nimodipine (do not discontinue)
• Induce hypertension: Target SBP 180-220 mmHg or 20-30% above baseline
• Use vasopressors such as noradrenaline or phenylephrine
• Maintain euvolaemia (avoid hypervolaemia - no benefit, increases complications)
• Optimise oxygenation and avoid hypocapnia

Definitive Treatment:

• Urgent cerebral angiography to confirm vasospasm
• Endovascular treatment options include:
  • Intra-arterial verapamil or nicardipine (local vasodilator)
  • Balloon angioplasty for severe focal vasospasm

Supportive Care:

• Maintain normoglycaemia
• Avoid hyperthermia
• Monitor for hydrocephalus requiring CSF drainage"

Examiner: Can you compare nimodipine with other calcium channel blockers in terms of its cerebral selectivity?

Candidate:

Cerebral Selectivity (2 marks):

"Nimodipine's cerebral selectivity is attributed to several factors:

High Lipophilicity: Nimodipine readily crosses the blood-brain barrier, achieving therapeutic concentrations in cerebral tissue. Other DHPs are less lipophilic and have limited CNS penetration.

Receptor Binding: Nimodipine has greater affinity for L-type calcium channels in cerebral vascular smooth muscle compared to peripheral vasculature.

State-Dependent Binding: Preferential binding to depolarised channels means ischaemic cerebral tissue (more depolarised) is preferentially affected.

Comparison:

• Amlodipine: Minimal cerebral selectivity, primarily peripheral
• Nifedipine: Some cerebral effect but less selective than nimodipine
• Nicardipine: IV formulation used for acute BP control but without the specific cerebral vasospasm evidence base
• Verapamil: Used intra-arterially for established vasospasm but not for prophylaxis"

Examiner: How would you manage a patient who develops severe hypotension on nimodipine?

Candidate:

Hypotension Management (3 marks):

"Hypotension from nimodipine requires a balanced approach as discontinuation removes cerebral protection.

Stepwise Approach:

Step 1: Optimise Contributing Factors

• Ensure adequate volume status
• Review other antihypertensives and vasoactive medications
• Check for other causes (sepsis, cardiac dysfunction, bleeding)

Step 2: Dose Reduction

• Reduce nimodipine to 30 mg every 4 hours
• This maintains some cerebral protection while reducing hypotension

Step 3: Vasopressor Support

• If hypotension persists despite dose reduction, consider low-dose vasopressor (noradrenaline infusion) to maintain adequate cerebral perfusion pressure while continuing nimodipine

Step 4: Route Consideration

• Avoid IV nimodipine as this causes more severe hypotension
• If absolutely necessary, use central line and very slow infusion with close monitoring

Targets:

• Maintain cerebral perfusion pressure more than 60 mmHg
• Avoid SBP less than 90 mmHg
• Balance nimodipine benefits against hypotension risks"

Total: 15 marks

---

References

1. Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol. 2017;8:286. PMID: 28611661

2. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens. 2011;13(9):687-689. PMID: 21896151

3. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447-1457. PMID: 10547409

4. Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. 1996;38(4):273-290. PMID: 8552787

5. Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med. 2004;116(1):35-43. PMID: 14706664

6. Prystowsky EN. Cardiovascular effects of calcium channel blockers. Clin Cardiol. 1987;10(9 Suppl 1):I17-22. PMID: 2822172

7. Gosselin S, Hoegberg LCG, Hoffman RS, et al. Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning. Clin Toxicol. 2016;54(10):899-923. PMID: 27402030

8. St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. Crit Care Med. 2017;45(3):e306-e315. PMID: 27749343

9. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521-555. PMID: 11031246

10. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198-205. PMID: 11805843

11. Striessnig J, Pinggera A, Kaber G, et al. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans. 2006;34(Pt 5):903-909. PMID: 17052224

12. Dolphin AC. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond. Nat Rev Neurosci. 2012;13(8):542-555. PMID: 22805911

13. Gollasch M, Nelson MT. Voltage-dependent Ca2+ channels in arterial smooth muscle cells. Kidney Blood Press Res. 1997;20(6):355-371. PMID: 9529363

14. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev. 2003;83(1):117-161. PMID: 12506128

15. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA. Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-396. PMID: 9131258

16. Triggle DJ. L-type calcium channels. Curr Pharm Des. 2006;12(4):443-457. PMID: 16472138

17. McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989;38(1):19-76. PMID: 2670511

18. Hamann SR, Blouin RA, McAllister RG Jr. Clinical pharmacokinetics of verapamil. Clin Pharmacokinet. 1984;9(1):26-41. PMID: 6362948

19. Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387-454. PMID: 3891302

20. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet. 1986;11(6):425-449. PMID: 3542337

21. Sorkin EM, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 1985;30(3):182-274. PMID: 2412780

22. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1991;41(3):478-505. PMID: 1711448

23. ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997. PMID: 12479763

24. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):895-906. PMID: 16154016

25. Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989;37(5):669-699. PMID: 2663433

26. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;(3):CD000277. PMID: 17636626

27. Sorkin EM, Clissold SP. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987;33(4):296-345. PMID: 3297616

28. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. Circulation. 1996;93(6):1262-1277. PMID: 8653857

29. Kapur PA, Bloor BC, Flacke WE, Olewine SK. Comparison of cardiovascular responses to verapamil during enflurane, isoflurane, or halothane anesthesia in the dog. Anesthesiology. 1984;61(2):156-160. PMID: 6465597

30. Reves JG. The relative hemodynamic effects of Ca++ entry blockers. Anesthesiology. 1984;61(1):3-5. PMID: 6742482

31. Wali FA. Interactions of neuromuscular blocking agents and calcium channel blockers at the mammalian motor nerve terminals. Fundam Clin Pharmacol. 1987;1(4):267-276. PMID: 2826288

32. Neal JM, Bernards CM, Butterworth JF 4th, et al. ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med. 2010;35(2):152-161. PMID: 20216033

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols in clinical practice.